Thyrocare Technologies Ltd
NSE:THYROCARE

Watchlist Manager
Thyrocare Technologies Ltd Logo
Thyrocare Technologies Ltd
NSE:THYROCARE
Watchlist
Price: 914.55 INR 0.64% Market Closed
Market Cap: 48.4B INR
Have any thoughts about
Thyrocare Technologies Ltd?
Write Note

Net Margin
Thyrocare Technologies Ltd

13.5%
Current
18%
Average
2.1%
Industry

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
13.5%
=
Net Income
839.7m
/
Revenue
6.2B

Net Margin Across Competitors

Country IN
Market Cap 48.4B INR
Net Margin
13%
Country US
Market Cap 78.1B USD
Net Margin
1%
Country US
Market Cap 74.5B EUR
Net Margin
1%
Country US
Market Cap 57.6B USD
Net Margin
1%
Country DE
Market Cap 25.5B EUR
Net Margin
3%
Country DE
Market Cap 18.9B EUR
Net Margin
-2%
Country US
Market Cap 19.2B USD
Net Margin
3%
Country US
Market Cap 17B USD
Net Margin
9%
Country DE
Market Cap 12.8B EUR
Net Margin
3%
Country US
Market Cap 12.6B USD
Net Margin
7%
Country AU
Market Cap 13.2B AUD
Net Margin
6%
No Stocks Found

Thyrocare Technologies Ltd
Glance View

Market Cap
48.4B INR
Industry
Health Care

Thyrocare Technologies Ltd. engages in provison of indepedent diagnostic and pathological laboratory services. The company is headquartered in Navi Mumbai, Maharashtra and currently employs 2,115 full-time employees. The company went IPO on 2016-05-09. The firm operates with a centralized processing laboratory (CPL) in Mumbai, India for esoteric tests, and regional processing laboratory in metro cities of India and other parts of Asia. The firm offers technologies, including Chemiluminescence Immunoassay (CLIA), Enzyme Linked Immunosorbent Assay (ELISA), High Performance Liquid Chromatography (HPLC), Capillary Electrophoresis (CE), Ion Selective Electrode (ISE), Fluorescence Flow Cytometry, Nephelometry, Photometry, Liquid Chromatography Mass Spectrometry (LC-MS), Inductively Coupled Plasma-Mass Spectrometry (ICP-MS) and Cytogenetics. The firm offers various kinds of tests, such as Aarogyam X, Aarogyam XL, Aarogyam 1.1, Aarogyam 1.2 and Covid Antibody GT. The company also offers Thyroxine (T4), Triiodothyronine (T3), Thyroid-stimulating hormone and Complete Vitamin Profile tests.

THYROCARE Intrinsic Value
677.88 INR
Overvaluation 26%
Intrinsic Value
Price
What is Net Margin?

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
13.5%
=
Net Income
839.7m
/
Revenue
6.2B
What is the Net Margin of Thyrocare Technologies Ltd?

Based on Thyrocare Technologies Ltd's most recent financial statements, the company has Net Margin of 13.5%.